Finally, a series of rescue experiments were implemented, and the results confirmed that BBOX1-AS1 promotes HCC progression and sorafenib resistance via the miR-361-3p/PHF8 axis. This evidence concerns the gene BBOX1 and hepatocellular carcinoma.